Publication
Title
Treating NASH by targeting peroxisome proliferator- activated receptors
Author
Abstract
The pathophysiology of non-alcoholic steatohepatitis (NASH) encompasses a complex set of intra-and extrahepatic driving mechanisms, involving numerous metabolic, inflammatory, vascular and fibrogenic pathways. The peroxisome proliferatoractivated receptors (PPARs) a, b/d and c belong to the nuclear receptor family of ligand-activated transcription factors. Activated PPARs modulate target tissue transcriptomic profiles, enabling the body's adaptation to changing nutritional, metabolic and inflammatory environments. PPARs hence regulate several pathways involved in NASH pathogenesis. Whereas single PPAR agonists exert robust anti-NASH activity in several preclinical models, their clinical effects on histological endpoints of NASH resolution and fibrosis regression appear more modest. Simultaneous activation of several PPAR isotypes across different organs and within-organ cell types, resulting in pleiotropic actions, enhances the therapeutic potential of PPAR agonists as pharmacological agents for NASH and NASH-related hepatic and extrahepatic morbidity, with some compounds having already shown clinical efficacy on histological endpoints.(c) 2023 European Association for the Study of the Liver. Published by Elsevier B.V. All rights reserved.
Language
English
Source (journal)
Journal of hepatology. - Amsterdam
Publication
Amsterdam : 2023
ISSN
0168-8278
DOI
10.1016/J.JHEP.2023.07.004
Volume/pages
79 :5 (2023) , p. 1302-1316
ISI
001105403800001
Pubmed ID
37459921
Full text (Publisher's DOI)
Full text (publisher's version - intranet only)
UAntwerpen
Faculty/Department
Research group
Publication type
Subject
Affiliation
Publications with a UAntwerp address
External links
Web of Science
Record
Identifier
Creation 09.01.2024
Last edited 28.08.2024
To cite this reference